Autolus Therapeutics Stock (NASDAQ: AUTL)

Autolus Therapeutics Stock (NASDAQ:AUTL), Trade Ideas

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Biotech

News

Penny Stocks

Health Care

Price Target

Small Cap

Analyst Ratings

Movers

Trading Ideas

General

AUTL

GILD

Truist has raised the price target for Autolus Therapeutics PLC (NASDAQ: AUTL) from $6 to $9 

Autolus Therapeutics&#39; Obe-Cel&#39;s Shows Compelling Safety Over Gilead&#39;s Drug For Acute Lymphoblastic Leukemia

Intraday Update

Markets

ACHR

ALGS

ANTE

ATNX

BBLN

BLBD

CRVS

DBVT

DRMA

DRTT

EAST

EFSH

GLDD

GLMD

HCDI

IBRX

IMPL

JAGX

JWAC

LMFA

Larimar Therapeutics, Inc. - Common Stock

LRMR

MGOL

MIND

MNDY

NGMS

NSPR

OCUP

ORMP

OSUR

PRSO

SANA

SBFM

SRPT

SWIM

THCH

TIVC

TTCF

TWST

VERO

WISA

WLDS

XBIO

XELA

ZAPP

ZKIN

Gainers


	NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.


Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

ALLK

COLB

PACW

YMAB

U.S. stocks traded lower, with the Dow Jones dropping around 100 points on Monday. Here are some big stocks recording gains in today’s session.

Sarepta Therapeutics, C3.ai, monday.com, And Other Big Stocks Moving Higher On Monday

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics PLC

Austal Ltd

<p>Benchmark  analyst Nathan Martin   reiterates Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Buy and maintains $277 price target.</p>


Reiteration

Benchmark Reiterates Buy on Norfolk Southern, Maintains $277 Price Target

WIIM

Vertiv Holdings shares are trading higher after multiple firms raised their respective price targets on the stock. Also, yesterday the company reported better-than-expected Q1 financial results and raised its 2024 guidance.

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Advanced Micro Devices</strong>.</p>
<p>Looking at options history for Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) we detected 12 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 58% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $145,646 and 7, calls, for a total amount of $703,721.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $135.0 to $195.0 for Advanced Micro Devices over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Advanced Micro Devices's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Advanced Micro Devices's substantial trades, within a strike price spectrum from $135.0 to $195.0 over the preceding 30 days.</p>
<h3>Advanced Micro Devices Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714056357_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/10/24</td>
<td>$9.95</td>
<td>$9.9</td>
<td>$9.9</td>
<td>$149.00</td>
<td>$304.9K</td>
<td>417</td>
<td>355</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$2.5</td>
<td>$2.47</td>
<td>$2.47</td>
<td>$152.50</td>
<td>$122.7K</td>
<td>6.2K</td>
<td>5.0K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$11.0</td>
<td>$10.9</td>
<td>$10.95</td>
<td>$160.00</td>
<td>$89.7K</td>
<td>2.9K</td>
<td>2.7K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$8.0</td>
<td>$7.95</td>
<td>$7.98</td>
<td>$170.00</td>
<td>$70.1K</td>
<td>3.2K</td>
<td>2.3K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$2.66</td>
<td>$2.64</td>
<td>$2.66</td>
<td>$165.00</td>
<td>$43.8K</td>
<td>6.6K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Advanced Micro Devices</h3>
<p>Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications, among others. AMD's traditional strength was in central processing units, CPUs, and graphics processing units, or GPUs, used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array, or FPGA, leader Xilinx to diversify its business and augment its opportunities in key end markets such as the data center and automotive.</p>
<p>Following our analysis of the options activities associated with Advanced Micro Devices, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Advanced Micro Devices</h3>
<ul>
<li>With a trading volume of 13,834,776, the price of AMD is up by 0.43%, reaching $152.39.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 5 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Advanced Micro Devices</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $205.0.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on Advanced Micro Devices with a target price of $200. </li>
<li>Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Advanced Micro Devices with a target price of $200. </li>
<li>In a cautious move, an analyst from Evercore ISI Group downgraded its rating to Outperform, setting a price target of $200. </li>
<li>An analyst from Wedbush downgraded its action to Outperform with a price target of $200. </li>
<li>An analyst from HSBC upgraded its action to Buy with a price target of $225. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Advanced Micro Devices, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Unpacking the Latest Options Trading Trends in Advanced Micro Devices

<p>Deep-pocketed investors have adopted a bearish approach towards Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WFC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Wells Fargo. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 25% leaning bullish and 50% bearish. Among these notable options, 2 are puts, totaling $90,790, and 6 are calls, amounting to $529,120.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $62.5 for Wells Fargo during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Wells Fargo's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Wells Fargo's whale trades within a strike price range from $25.0 to $62.5 in the last 30 days. </p>
<h3>Wells Fargo Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714056351_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$23.0</td>
<td>$21.5</td>
<td>$21.6</td>
<td>$40.00</td>
<td>$216.0K</td>
<td>20.2K</td>
<td>0</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$18.35</td>
<td>$16.35</td>
<td>$17.1</td>
<td>$45.00</td>
<td>$171.0K</td>
<td>18.2K</td>
<td>100</td>
</tr>
<tr>
<td>WFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$4.6</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$62.50</td>
<td>$56.2K</td>
<td>762</td>
<td>125</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$0.54</td>
<td>$0.53</td>
<td>$0.53</td>
<td>$60.00</td>
<td>$42.3K</td>
<td>5.4K</td>
<td>243</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$1.0</td>
<td>$0.98</td>
<td>$0.98</td>
<td>$60.00</td>
<td>$39.1K</td>
<td>2.6K</td>
<td>1.4K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Wells Fargo</h3>
<p>Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.</p>
<p>Having examined the options trading patterns of Wells Fargo, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Wells Fargo</h3>
<ul>
<li>With a trading volume of 3,190,470, the price of WFC is down by -0.6%, reaching $60.23.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wells Fargo options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Wells Fargo's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bearish approach towards Hecla Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HL#NYSE">HL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Hecla Mining. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 0% leaning bullish and 100% bearish. Among these notable options, 5 are puts, totaling $291,252, and 4 are calls, amounting to $142,794.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $5.0 to $6.0 for Hecla Mining over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Hecla Mining's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Hecla Mining's whale trades within a strike price range from $5.0 to $6.0 in the last 30 days. </p>
<h3>Hecla Mining 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714056346_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.38</td>
<td>$0.37</td>
<td>$0.38</td>
<td>$5.00</td>
<td>$95.2K</td>
<td>2.4K</td>
<td>4.9K</td>
</tr>
<tr>
<td>HL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.39</td>
<td>$0.38</td>
<td>$0.39</td>
<td>$5.00</td>
<td>$78.2K</td>
<td>2.4K</td>
<td>3</td>
</tr>
<tr>
<td>HL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.37</td>
<td>$0.36</td>
<td>$0.37</td>
<td>$5.00</td>
<td>$54.7K</td>
<td>2.4K</td>
<td>8.0K</td>
</tr>
<tr>
<td>HL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.18</td>
<td>$0.16</td>
<td>$0.16</td>
<td>$6.00</td>
<td>$40.2K</td>
<td>13.0K</td>
<td>352</td>
</tr>
<tr>
<td>HL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.38</td>
<td>$0.36</td>
<td>$0.38</td>
<td>$5.00</td>
<td>$38.0K</td>
<td>2.4K</td>
<td>6.0K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hecla Mining</h3>
<p>Hecla Mining Co produces and explores silver, gold, zinc and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Nevada Operations. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada , United States and Mexico and it derives a majority of its revenue from United States.</p>
<p>After a thorough review of the options trading surrounding Hecla Mining, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Hecla Mining Standing Right Now?</h3>
<ul>
<li>With a volume of 5,163,132, the price of HL is down -4.01% at $5.03. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 13 days.</li>
</ul>
<h3>What The Experts Say On Hecla Mining</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $6.0.</p>
<ul>
<li>An analyst from Roth MKM has decided to maintain their Buy rating on Hecla Mining, which currently sits at a price target of $6. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Hecla Mining, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Behind the Scenes of Hecla Mining's Latest Options Trends

<p>Benchmark  analyst Mark Levin   reiterates Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Hold.</p>


Benchmark Reiterates Hold on Canadian Pacific Kansas

<p>UBS  analyst Michael Goldsmith   upgrades UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) from Neutral to Buy and raises the price target from $38 to $44.</p>


Upgrades

UBS Upgrades UDR to Buy, Raises Price Target to $44

<p><strong>OUTLOOK</strong></p>
<p>"In the near-term, demand in key end-markets from packaging and mobility to energy applications are trending sequentially higher and in-line with our expectations at the start of the year," said Fitterling. "In addition, our high-value organic growth investments and our advantaged portfolio position Dow well to deliver earnings growth and enhanced shareholder value as the economic recovery gathers strength. This allows us the financial flexibility to advance our long-term Decarbonize &amp; Grow and Transform the Waste strategies and capture more than $3 billion in underlying earnings improvement annually by 2030. We will share more about our strategic and financial priorities that will drive earnings growth and enable higher shareholder returns at our upcoming Investor Day on May 16, 2024."</p>


Guidance

Dow Inc Chairperson Jim Fitterling In Q1 Report, Said "In The Near-Term, Demand In Key End-Markets From Packaging And Mobility To Energy Applications Are Trending Sequentially Higher And In-Line With Our Expectations At The Start Of The Year"

<p>Benchmark  analyst Mark Zgutowicz   reiterates Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Hold.</p>


Benchmark Reiterates Hold on Meta Platforms

<p><strong>Lockheed Martin Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) released its Q1 earnings report on Tuesday, which showed impressive growth <a href="https://www.benzinga.com/quote/LMT/news">in net sales</a>. </p>
<p>The company reported net sales of $17.195 billion, marking a 13.7% increase compared to the same quarter last year. Despite this strong performance, adjusted earnings per share (EPS) fell slightly to $6.33 from $6.43 year-over-year (YoY). However, the EPS still exceeded expectations by a notable margin.</p>
<p><em>More on the earnings, here: <a href="https://www.benzinga.com/news/earnings/24/04/38383997/lockheed-martins-q1-revenue-climbs-amid-fluctuating-profit-margins-2024-outlook-reaffirmed">Lockheed Martin&#8217;s Q1 Revenue Climbs Amid Fluctuating Profit Margins, 2024 Outlook Reaffirmed</a></em></p>
<p>Lockheed Martin stock has been relatively stable, down a modest 4.53% over the past year and up 1.30%  year-to-date (YTD). Despite this, a technical analysis has identified signs that a Golden Cross, a potentially bullish indicator, might be approaching, suggesting a possible positive trend reversal for the stock.</p>
<h2 class="wp-block-heading">Positive Trend Reversal &#8211; Golden Cross In Sight</h2>
<p>The current trend for Lockheed Martin is moderately bullish, with slight selling pressure. Several key technical indicators support this outlook.</p>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="625" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25075344/Screenshot-2024-04-25-at-4.37.49-PM.png" alt="" class="wp-image-308555" style="width:800px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25075344/Screenshot-2024-04-25-at-4.37.49-PM.png 625w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25075344/Screenshot-2024-04-25-at-4.37.49-PM-300x218.png 300w" sizes="(max-width: 625px) 100vw, 625px" /></figure></p>
<p><em><a target="_blank" href="https://pro.benzinga.com/dashboard" rel="noreferrer noopener">Chart: Benzinga Pro</a></em></p>
<p>The stock&#8217;s current price is $459.14, slightly above its 8-day SMA of $457.99 and the 20-day SMA of $454.67, signaling a bullish trend. It also trades above the 50-day SMA of $441.38 and the 200-day SMA of $442.31, reinforcing the long-term bullish outlook.</p>
<p>One traditionally bullish signal is the <strong>Golden Cross</strong>, where the 50-day SMA is about to cross above the 200-day SMA. If a Golden Cross were to occur, it would indicate bullish potential for the stock.</p>
<p><figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="625" height="454" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25075548/Screenshot-2024-04-25-at-5.25.09-PM.png" alt="" class="wp-image-308562" style="width:800px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25075548/Screenshot-2024-04-25-at-5.25.09-PM.png 625w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/25075548/Screenshot-2024-04-25-at-5.25.09-PM-300x218.png 300w" sizes="(max-width: 625px) 100vw, 625px" /></figure></p>
<p><em><a target="_blank" href="https://pro.benzinga.com/dashboard" rel="noreferrer noopener">Chart: Benzinga Pro</a></em></p>
<p>The Moving Average Convergence Divergence (MACD) indicator for Lockheed Martin is 4.74, reinforcing the bullish signal. However, the Relative Strength Index (RSI) is at 61.72, with the stock treading near the overbought zone above 70.</p>
<p>Looking at the Bollinger Bands, the stock price continues to lie in the upper (bullish) band, also suggesting a bullish trend.</p>
<p>Overall, while there are multiple signs of a bullish trend, the RSI indicates caution as the stock may soon be overbought. Investors should consider these technical indicators along with other factors before making investment decisions.</p>
<h2 class="wp-block-heading"><strong>Analysts See 10%+ Upside</strong></h2>
<p>Despite the positive technical signals, analyst ratings for Lockheed Martin Corp are Neutral, with a <a href="https://www.benzinga.com/quote/LMT/analyst-ratings">consensus price target</a> of $444. The most recent analyst ratings from Deutsche Bank, Citigroup, and UBS, released over the past two days, suggest an average price target of $503.67. This implies a potential upside of 10.21% from the current price.</p>
<p>While Lockheed Martin&#8217;s Q1 2024 earnings report demonstrated strong sales growth, its stock has not seen significant movement recently. </p>
<p>However, the technical analysis suggests a potential bullish trend. Investors should consider these factors along with analyst ratings and consensus targets before making any investment decisions regarding Lockheed Martin stock.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38414013/lockheed-martin-reports-q1-earnings-beat-but-margin-concerns-remain-analysts-dive-i">Lockheed Martin Reports Q1 Earnings Beat, But Margin Concerns Remain: Analysts Dive Into Results, Outlook</a></em></p>
<p><em>Photo: Shutterstock</em></p>


Analyst Color

Earnings

Technicals

Lockheed Martin Set For Lift-Off: Is A Golden Cross On The Horizon?

Dow Sees Strong Demand Growth From Autos, Data Centers, Chips

<p><em>Editor&#8217;s note: This story has been updated to correct an error in Personal Consumption Expenditure data.</em></p>
<p>The U.S. economy grew in the first quarter of the year, albeit at a markedly slower pace compared to the final quarter of 2023 <a href="https://www.benzinga.com/topic/economics">and below economists&#8217; predictions.</a></p>
<p>The annualized growth rate of the Gross Domestic Product (GDP) stood at 1.6% for the recently concluded quarter, according to the advanced estimates released by the Bureau of Economic Analysis on Thursday.  </p>
<h3 class="wp-block-heading">Q1 2024 GDP: Key Highlights</h3>
<ul>
<li>A growth rate of 1.6% in Q1 marks a notable slowdown from the 3.4% in the final quarter of 2023, and it fell short of the forecasted 2.5% growth according to the economist consensus.</li>
<li>Core Personal Consumption Expenditure (PCE) price index – Fed&#8217;s favorite inflation gauge – rose from 3.4% in Q4 2023 to 3.7% in Q1 2024, beating the expected 2%.</li>
<li>Headline PCE price rose from 1.8% in Q4 2023 to 3.4% </li>
<li>Real consumer spending growth slowed from 3.5% to 2.5%, below the expected 2.8%.  </li>
</ul>
<h3 class="wp-block-heading"><strong>Market Reactions</strong></h3>
<p>The U.S. dollar index (DXY), as tracked by the <strong>Invesco DB USD Index Bullish Fund ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), inched higher by 0.1% minutes after the GDP print. </p>
<p>Treasury yields slightly rose by approximately 3 basis points across the curve, with the policy-sensitive 2-year yield rising to 4.95%, as traders bolstered their expectations for fewer and delayed Fed rate cuts in light of the higher-than-expected inflation figures.</p>
<p>Gold, as tracked by the <strong>SPDR Gold Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), went up 0.5%</p>
<p>During Thursday&#8217;s premarket trading, futures on major U.S. indices were all in the red, driven by a sharp drop of about 15% in tech giant <strong>Meta Platforms Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) following the issuance of a weak revenue guidance for the second quarter, overshadowing the company&#8217;s better-than-expected first quarter results.</p>
<p><em>Now Read:</em> <em><a href="https://www.benzinga.com/economics/macro-economic-events/24/04/38410454/treasury-yields-reach-5-month-high-lift-mortgage-rates-expert-warns-federal-debt-">Treasury Yields Reach 5-Month High, Lift Mortgage Rates; Expert Warns &#8216;Federal Debt Blob Is Out Of Control&#8217;</a></em></p>
<p><em>Image: Shutterstock</em></p>


Macro Economic Events

Macro Notification

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

US Economy Grows 1.6% In Q1, Sharply Below Expectations As Price Pressures Weigh On Spending (CORRECTED)

<p>During the recent <strong>Benzinga Cannabis Capital Conference</strong>, <strong>Rebecca Koar</strong>, executive vice president of investor relations &amp; strategy at <strong>Ascend Wellness Holdings</strong>, highlighted significant developments in the company's operations, particularly in Massachusetts. </p>
<h2 class="wp-block-heading">Enhancing Supply Capabilities</h2>
<p>Koar noted that Ascend&#8217;s<strong> Simply Herba</strong>l brand has emerged as the top brand in the state, a notable achievement given that it was launched just two years ago. &#8220;Our <strong>Simply Herbal </strong>brand has become the number one brand,&#8221; Koar stated, attributing the success to the company&#8217;s strategic placement of three dispensaries and a new outlet in New Bedford that opened last year.</p>
<p>To support increasing demand, Ascend Wellness has expanded its cultivation capabilities. &#8220;We previously had about 42,000 square feet of cultivation in Massachusetts,&#8221; Koar explained. &#8220;We just announced an acquisition a couple of months ago in Amesbury, Massachusetts, for a second cultivation facility.&#8221; This new facility adds 15,000 square feet of additional canopy and includes a kitchen, enabling the company to introduce gummies.</p>
<h2 class="wp-block-heading">Financial Health and Strategic Moves</h2>
<p>Ascend Wellness has reported a strong financial outlook, with positive cash flow from operations and free cash flow for 2023. &#8220;We announced positive cash flow from operations for the entire year and positive free cash flow,&#8221; said Koar, underlining the company&#8217;s financial stability since its founding in 2018. This financial health positions Ascend well for upcoming financial maneuvers, including a planned refinancing and debt repayment strategy for next year.</p>
<h2 class="wp-block-heading">Preparing for Expansion in New Markets</h2>
<p>With new states legalizing adult-use cannabis, Ascend Wellness is preparing to enter these emerging markets while strengthening its presence in existing ones. Koar shared that Ohio and Pennsylvania are potential new markets, with Pennsylvania&#8217;s progress hinging on legislative developments. &#8220;We&#8217;re constantly looking at what states we want to be in,&#8221; she mentioned, emphasizing the importance of strategic market selection.</p>
<h2 class="wp-block-heading">Networking and Learning Opportunities at the Conference</h2>
<p>Koar also discussed the importance of the conference for networking and learning from industry peers. &#8220;Our biggest priority was meeting with our sell-side analysts this morning,&#8221; she revealed. The interactions included discussions with buy-side investors and panel participation by Ascend&#8217;s CEO, which Koar described as very successful. Through these engagements, the company aims to share and gather valuable practices within the industry.</p>
<p><em>Image: Boston</em> Shutterstock</p>


Ascend Wellness Strengthens Position in Massachusetts Cannabis Market

<p>Roth MKM  analyst George Kelly   reiterates Mama`s Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) with a Buy and raises the price target from $6 to $6.5.</p>


MAMA

Roth MKM Reiterates Buy on Mama's Creations, Raises Price Target to $6.5

<p>Cantor Fitzgerald  analyst Sarah James   maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $391 to $360.</p>


Cantor Fitzgerald Maintains Neutral on Humana, Lowers Price Target to $360

MORN

Morningstar shares are trading lower. The company reported Q1 financial results.

<p>UBS  analyst Dennis Geiger   maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Buy and raises the price target from $3400 to $3500.</p>


UBS Maintains Buy on Chipotle Mexican Grill, Raises Price Target to $3500

<p>Roth MKM  analyst Sean McGowan   maintains MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) with a Buy and lowers the price target from $100 to $95.</p>


MGPI

Roth MKM Maintains Buy on MGP Ingredients, Lowers Price Target to $95

Graco shares are trading lower after the company reported worse-than-expected Q1 financial results.

<p>UBS  analyst Stephen Ju   maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and lowers the price target from $610 to $575.</p>


UBS Maintains Buy on Meta Platforms, Lowers Price Target to $575

Autolus Therapeutics GAAP EPS of -$1.20 misses by $0.10, revenue of $1.69M misses by $0.01M

Autolus Therapeutics Plc ADR (AUTL) said before open Thursday that it lost $0.45 per share in quarter four 2023.  The company reported $0.00 in revenueIn the same quarter a year ago, the company lost $0.23 per share on revenue of $3.8 million. The stock is up 8.39% to $5.94 after the report.Despite Autolus Therapeutics Plc

Autolus Therapeutics Plc ADR Up 8.39% To $5.94 After Earnings Miss

Autolus Therapeutics plc 2023 Q4 - Results - Earnings Call Presentation

An announcement from Autolus Therapeutics Plc (AUTL) is now available. On March 14, 2024, the Company will share its annual results using an update...

Autolus Therapeutics Announces Annual Results and CDO Resignation

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM – Research Report), Coheru...

Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)

Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript

Autolus Therapeutics (AUTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu f...

Buy Rating Affirmed for Autolus Therapeutics Amid Strong Progress and Potential of Obe-cel

The latest announcement is out from Autolus Therapeutics Plc (AUTL). John Johnson has stepped down from his role as the chair of Autolus Therapeuti...

Autolus Therapeutics Announces Board Leadership Changes

GLYC, APLD and AUTL are among after hour movers

In a report released today, Gil Blum from Needham maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of ...

Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook

APLD

CADL

CGEM

CHRS

ELYM

GLYC

LYEL

NRIX

SCRM

TRDA

Financing

Press Releases

Autolus Announces Pricing of Underwritten Offering

Autolus Therapeutics announces publication in Nature Communications

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Autolus Therapeutics announces publication in Blood Cancer Journal

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Management

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO